Loading...
•
Jun 30
Amicus Therapeutics Q2 2025 Earnings Report
Amicus Therapeutics reported its financial results for the second quarter of 2025, highlighting strong revenue growth and progress in its clinical programs.
Key Takeaways
Amicus Therapeutics delivered robust second-quarter growth, with total revenue increasing by 18% at constant exchange rates, driven by strong commercial execution for both Galafold and Pombiliti + Opfolda. The company reiterated its 2025 financial guidance, including expectations for GAAP profitability in the second half of 2025, and anticipates exceeding $1 billion in total revenue by 2028.
Total revenue for Q2 2025 reached $154.7 million, marking an 18% increase at constant exchange rates year-over-year.
Galafold revenue grew by 12% at constant exchange rates to $128.9 million, while Pombiliti + Opfolda revenue surged by 58% at constant exchange rates to $25.8 million.
GAAP net loss was $24.4 million, or $0.08 per share, while non-GAAP net income was $1.9 million, or $0.01 per share.
The company is on track for full enrollment in the ACTION3 study of DMX-200 by year-end and expects to achieve GAAP profitability in the second half of 2025.
Amicus Therapeutics
Amicus Therapeutics
Amicus Therapeutics Revenue by Segment
Revenue by Segment
Galafold Revenue
CapyFin.comPombiliti + Opfolda Revenue
CapyFin.com Forward Guidance
Amicus Therapeutics reiterated its full-year 2025 financial guidance, expecting continued strong revenue growth and achieving GAAP profitability in the second half of the year, with a long-term goal of exceeding $1 billion in total revenue by 2028.
Positive Outlook
- Reiterating 2025 financial guidance for total revenue growth of 15% to 22%.
- Galafold revenue growth expected to be 10% to 15% for 2025.
- Pombiliti + Opfolda revenue growth expected to be 50% to 65% for 2025.
- Anticipates achieving GAAP net income (profitability) during the second half of 2025.
- Gross Margin expected to be in the mid-80% range for 2025.
Challenges Ahead
- Non-GAAP operating expenses are projected to be $380 million to $400 million, including a $30 million upfront license payment, indicating significant ongoing expenditures.
- The company's current cash position reflects the $30 million upfront payment for the DMX-200 licensing agreement, impacting cash and cash equivalents.
- Continued reliance on successful commercial execution and new patient starts for revenue growth.
- Potential for regulatory delays or unsuccessful negotiations with pricing and reimbursement authorities.
- The variability of excluded items in non-GAAP measures may have a significant and unpredictable impact on future GAAP results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income